Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee hands down positive opinion for Kineret in Still's disease

Feb. 26, 2018

Xgeva recommended for E.U. approval to prevent skeletal-related events in multiple myeloma

Feb. 26, 2018

EMA committee hands down negative opinion on Puma's neratinib

Feb. 26, 2018

EMA committee recommends against expanding use of Sutent in adults at high risk of recurrent RCC

Feb. 26, 2018

CHMP adopts positive opinion for Lynparza tablets in platinum-sensitive relapsed ovarian cancer

Feb. 26, 2018

EMA committee communicates positive trend vote for rucaparib

Feb. 22, 2018

EMA grants ATMP classification to Regeneus' Progenza

Feb. 15, 2018

EMA accepts Epidiolex MAA for review

Feb. 6, 2018

EMA accepts fremanezumab MAA

Feb. 5, 2018

Pfizer reflects on milestones of fourth quarter 2017

Feb. 5, 2018

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...